Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gentle
San Francisco, California, United Statesgentle.ai ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Gentle is a biotechnology company developing a "programmable biology" platform designed to streamline the engineering of biological systems. Founded by Ariel Weinberger, who previously founded a molecular biology software company also named Gentle (acquired by Benchling), the company aims to build the foundational "operating system" for biology. Gentle leverages advanced genomics, synthetic biology, and software engineering to enable more predictable and scalable biological design and experimentation. The company is currently in an early/stealth stage, focusing on infrastructure that bridges the gap between digital design and physical biological execution.
- Modalities
- Synthetic biologyGenomics platform
- Industry
- Non-Drug Biotech
Beyond the preview
Go deeper on Gentle.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gentle.